Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Donanemab, developed by Eli Lilly, is another promising monoclonal antibody targeting amyloid-beta. In a phase 3 randomized clinical trial, donanemab slowed clinical disease progression in ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

AN ALZHEIMER’S drug hailed as a ‘miracle’ medicine for dementia may cause life-threatening brain bleeds in a third of ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Vaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...

Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, ...

A so-called 'miracle' Alzheimer's drug caused brain bleeds in more than a third of patients, a new study has revealed.

Such tests are increasingly moving beyond their origins in cutting-edge research and into the laboratory and diagnostic ...

This is the second time NICE made a decision not to approve these treatments for NHS use. Leqembi, marketed by Biogen and ...

NICE is seeking public comment on the updated draft guidances through March 27, with plans to issue final draft guidances in July.